The eEF2 kinase coordinates the DNA damage response to cisplatin by supporting p53 activation

Area of Science:

• Molecular Biology
• Cell Biology
• Genetics

Background:

• Eukaryotic elongation factor 2 kinase (eEF2K) is a stress-responsive enzyme that regulates mRNA translation.
• eEF2K's role in DNA damage response, particularly to cisplatin-induced DNA crosslinks, is currently unknown.
• Cisplatin is a widely used chemotherapy agent that induces DNA crosslinks, leading to cell death.

Purpose of the Study:

• To investigate the role of eEF2K in the cellular response to cisplatin treatment.
• To elucidate the molecular mechanisms by which eEF2K mediates cisplatin sensitivity or resistance.
• To determine if eEF2K is a potential therapeutic target for enhancing cisplatin chemotherapy.

Main Methods:

• Cell culture experiments using eEF2K deficient and wild-type cells.
• Assessment of DNA damage response pathways (ATM, ATR, p53) activation.
• Measurement of cisplatin-induced apoptosis and cell viability.
• Analysis of DNA repair protein expression (ERCC1).
• In vivo studies using Caenorhabditis elegans (efk-1 ortholog deletion).

Main Results:

• eEF2K deficient cells exhibit increased resistance to cisplatin treatment.
• Loss of eEF2K impairs the activation of ATM and ATR DNA damage response pathways.
• eEF2K deficiency prevents p53 activation and reduces cisplatin-induced apoptosis.
• Absence of eEF2K delays the resolution of cisplatin-induced DNA damage.
• eEF2K promotes the expression of the DNA repair protein ERCC1.
• Deletion of the eEF2K ortholog (efk-1) in C. elegans mitigates cisplatin-induced germ cell death.

Conclusions:

• eEF2K is a critical mediator of the cellular response to cisplatin-induced DNA damage.
• eEF2K promotes cisplatin-induced apoptosis via p53 activation and facilitates DNA repair.
• Targeting eEF2K could be a strategy to modulate sensitivity to cisplatin chemotherapy.
• eEF2K's role in DNA damage response is evolutionarily conserved.